247 related articles for article (PubMed ID: 11916503)
21. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma.
Shibagaki I; Tanaka H; Shimada Y; Wagata T; Ikenaga M; Imamura M; Ishizaki K
Clin Cancer Res; 1995 Jul; 1(7):769-73. PubMed ID: 9816044
[TBL] [Abstract][Full Text] [Related]
22. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.
Taylor AC; Shu L; Danks MK; Poquette CA; Shetty S; Thayer MJ; Houghton PJ; Harris LC
Med Pediatr Oncol; 2000 Aug; 35(2):96-103. PubMed ID: 10918230
[TBL] [Abstract][Full Text] [Related]
23. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
Pilotti S; Della Torre G; Lavarino C; Di Palma S; Sozzi G; Minoletti F; Rao S; Pasquini G; Azzarelli A; Rilke F; Pierotti MA
J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
[TBL] [Abstract][Full Text] [Related]
24. Human papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53, p21, mdm2, C-erbB2 and impact on survival.
Bahnassy AA; Zekri AR; Abdallah S; El-Shehaby AM; Sherif GM
Pathol Int; 2005 Feb; 55(2):53-62. PubMed ID: 15693850
[TBL] [Abstract][Full Text] [Related]
25. Altered patterns of MDM2 and TP53 expression in human bladder cancer.
Lianes P; Orlow I; Zhang ZF; Oliva MR; Sarkis AS; Reuter VE; Cordon-Cardo C
J Natl Cancer Inst; 1994 Sep; 86(17):1325-30. PubMed ID: 8064890
[TBL] [Abstract][Full Text] [Related]
26. Overexpressed TP73 induces apoptosis in medulloblastoma.
Castellino RC; De Bortoli M; Lin LL; Skapura DG; Rajan JA; Adesina AM; Perlaky L; Irwin MS; Kim JY
BMC Cancer; 2007 Jul; 7():127. PubMed ID: 17626635
[TBL] [Abstract][Full Text] [Related]
27. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
[TBL] [Abstract][Full Text] [Related]
28. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
[TBL] [Abstract][Full Text] [Related]
29. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation.
Pruneri G; Carboni N; Baldini L; Intini D; Colombi M; Bertolini F; Valentini S; Maisonneuve P; Viale G; Neri A
Hum Pathol; 2003 Jan; 34(1):41-7. PubMed ID: 12605365
[TBL] [Abstract][Full Text] [Related]
30. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.
Higashiyama M; Doi O; Kodama K; Yokouchi H; Kasugai T; Ishiguro S; Takami K; Nakayama T; Nishisho I
Br J Cancer; 1997; 75(9):1302-8. PubMed ID: 9155050
[TBL] [Abstract][Full Text] [Related]
31. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
[TBL] [Abstract][Full Text] [Related]
32. MDM2 amplification, P53 mutation, and accumulation of the P53 gene product in malignant fibrous histiocytoma.
Reid AH; Tsai MM; Venzon DJ; Wright CF; Lack EE; O'Leary TJ
Diagn Mol Pathol; 1996 Mar; 5(1):65-73. PubMed ID: 8919547
[TBL] [Abstract][Full Text] [Related]
33. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.
Gottlieb A; Althoff K; Grunewald L; Thor T; Odersky A; Schulte M; Deubzer HE; Heukamp L; Eggert A; Schramm A; Schulte JH; Künkele A
Oncotarget; 2017 Apr; 8(17):27882-27891. PubMed ID: 28427187
[TBL] [Abstract][Full Text] [Related]
34. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
35. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
[TBL] [Abstract][Full Text] [Related]
36. Biochemical uncovering of mdm2/p53 complexes in liposarcomas parallels their immunohistochemical detection.
Butò S; Pierotti MA; Tamborini E; Della Torre G; Lavarino C; Rilke F; Pilotti S
Diagn Mol Pathol; 1999 Sep; 8(3):125-30. PubMed ID: 10565683
[TBL] [Abstract][Full Text] [Related]
37. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.
Flørenes VA; Maelandsmo GM; Forus A; Andreassen A; Myklebost O; Fodstad O
J Natl Cancer Inst; 1994 Sep; 86(17):1297-302. PubMed ID: 8064888
[TBL] [Abstract][Full Text] [Related]
38. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias.
Wojcik I; Szybka M; Golanska E; Rieske P; Blonski JZ; Robak T; Bartkowiak J
Neoplasma; 2005; 52(4):318-24. PubMed ID: 16059649
[TBL] [Abstract][Full Text] [Related]
39. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
[TBL] [Abstract][Full Text] [Related]
40. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma.
Fulop V; Mok SC; Genest DR; Gati I; Doszpod J; Berkowitz RS
J Reprod Med; 1998 Feb; 43(2):119-27. PubMed ID: 9513873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
